VAXX (Vaxxinity) Cash-to-Debt : 2.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vaxxinity's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.00.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vaxxinity could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Vaxxinity's Cash-to-Debt or its related term are showing as below:

VAXX's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.46
* Ranked among companies with meaningful Cash-to-Debt only.

Vaxxinity Cash-to-Debt Historical Data

The historical data trend for Vaxxinity's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vaxxinity Cash-to-Debt Chart

Vaxxinity Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.03

0.81

13.54

5.97

2.00

Vaxxinity Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											5.97	4.83	4.07	3.20	2.00

Competitive Comparison of Vaxxinity's Cash-to-Debt

For the Biotechnology subindustry, Vaxxinity's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxxinity's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vaxxinity's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Vaxxinity Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vaxxinity's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	30.395	/	(1.906	+	13.262)
	=	2.00

Vaxxinity's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	30.395	/	(1.906	+	13.262)
	=	2.00

Vaxxinity (OTCPK:VAXX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vaxxinity Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vaxxinity's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxxinity Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Odyssey Way, Merritt Island, FL, USA, 32953

Website

https://www.vaxxinity.com

Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.

Executives

Sumita Ray	officer: Chief Legal Officer, Secretary	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp	10 percent owner	P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano	director	209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese	director, officer: Executive Chairman	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu	director, 10 percent owner, officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc	10 percent owner	25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss	10 percent owner	126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile	officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig	director	625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui	director	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292